Bo InnoHealth is a spin-off from the Hong Kong Polytechnic University developing a novel microencapsulation technology which can protect probiotics and probiotics and enable their use in a wider range of applications such as snacks, hot drinks and pet food. The company’s approach is based on using mushroom cells as a protective material to make […]
Talus Bio aims to revolutionize drug development for gene regulators by enabling the ability to study gene regulatory proteins (GRPs) in a living cell environment. The company’s initial focus is on small-molecule drug development in oncology. Founded in 2020 as a spin out of the University of Washington and Altius Institute for Biomedical Sciences, the […]
Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients. The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 […]
Leyden Labs is developing broad spectrum antivirals that target commonalities of viral families, potentially offering protection against known viruses as well as new viruses as they emerge. The company was founded in 2020 in response to the COVID-19 pandemic by Koenraad Wiedhaup, a former partner at McKinsey & Co, and three previous executives of Crucell, […]
Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Unravel Biosciences has developed a vertically integrated computational platform to discover better drug targets. Instead of classic pharma, which takes a target of interest and develops drugs to bind that specific target, Unravel’s platform screens many drugs in parallel for their real-world impact […]
Vernal Biosciences is aiming to democratize access to mRNA manufacturing technologies, with the goal of accelerating the clinical impact of mRNA as a foundational therapeutic modality. Vernal is focused on achieving and maintaining high purity throughout the scaling of all mRNA manufacturing processes for clients in the research and ultimately clinical stages. The company wants […]
AVVantgarde Bio is a gene therapy startup that has developed two adeno-associated viral (AAV)-based platforms with increased transfer capabilities to enable the delivery of large genes. Gene therapy based on AAV vectors has proven effective for several forms of genetic blindness, however the small vector payload may limit their further application. The company’s two AAV-based […]
Kuano is aiming to transform the discovery of enzyme inhibitor drugs using a platform that combines quantum transition state simulation and AI led chemistry. Enzyme catalysis occurs via thermodynamically favoured quantum transition states, which represent an attractive conformation for targeting enzyme inhibitors. Kuano’s proprietary in silico approach rapidly simulates the quantum transition state and generates […]
Nuevocor is a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies. The company’s lead programme is an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene. The company also plans to address other untreatable cardiomyopathies using their novel target discovery platform. […]
Cutanos, a spin-off from the Max Planck Society, is developing dermal targeted delivery systems for novel vaccines and immunotherapies. Delivery of antigens to specialised immune cells, called dendritic cells (DCs), is a promising approach to developing innovative vaccines, as well as immunotherapies against cancer and autoimmune diseases. However, there are different subsets of DCs which […]